TLR7 agonists

A compound having the structure of Formula I:

• wherein
• R1 is independently —H, —OH, —O—C(O)—R8 or —F,
• R2 is independently —H, —OH, —O—C(O)—R8 or —F,
• R3 is —OH, or —O—C(O)—R8,
• R4 is —H, —OH, —O—C(O)—R8 or —(C1-C8)alkyl,
• wherein R3 and R4 can be in the form of a carbonyl oxygen (═O),
• R5 is —H, —OH, —O—C(O)—R8, —(C1-C8)alkyl, —O—(C1-C8)alkyl, —NH2 or —NHR8
• wherein R4 and R5 can form a 3-6 membered cycloalkyl ring,
• R6 is —H, —(C1-C8)alkyl, —C(H)═CH2, —C(H)═CH(C1-C8)alkyl), —C(H)═C(C1-C8)alkyl)(C1-C8)alkyl), —C(H)═C═CH2, —C(H)═C═C(C1-C8)alkyl)H, —CH2C≡CH, —OH or —O(C1-C8)alkyl,
• R7 is —H, —OH, —OCH3, —SH or —Cl,
• R8 is independently —(C1-C8)alkyl, aryl, —(CH2)n(aryl), heteroaryl or —(CH2)n(heteroaryl),
• n is an integer 1, 2, 3, 4 or 5,
• wherein at least one R4 or R5 is not —H,
• wherein each alkyl, cycloalkyl, aryl and heteroaryl are independently optionally substituted by one or more of CN, NO2, halogen, (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C3)cycloalkyl, aryl, heteroaryl, OH, alkenyl, alkynyl, O—(C1-C3)alkyl, O—C(O)—R9, O-(alkylene)aryl, O-(alkylene)heteroaryl, C(O)R9, S(C1-C8)alkyl, S(O)(C1-C8)alkyl, SO2(C1-C8)alkyl, C(O)OR9, C(O)NR9R9, C(O)NR9SO2(C1-C8)alkyl, NR9R9, NR9(CO)OR9, NH(CO)R9, NH(SO2)(C1-C8)alkyl or NH(SO2)NR9R9, and R9 is independently —H, —OH, —(C1-C8)alkyl, cycloalkyl, heterocyclyl, or the two R9's of C(O)NR9R9 or NR9R9 combine together with the nitrogen atom to form a heterocycle;
• or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.